PHENOTYPIC SCREENING
DefiniGEN's Phenotypic Screening Service helps you move quickly and efficiently from screening library to promising candidates by combining our expertise at generating iPSC-derived hepatocyte cellular models of disease with our wide panel of bespoke bioassays.
We work as partners with your team to design and implement in-house screening of small molecule and RNAi/oligonucleotide therapeutics, so you can advance your program at speed.
When you choose DefiniGEN's Phenotypic Screening Service, you don't just get access to extra hands and fully equipped labs, you get scientific partners with experience in different aspects of drug discovery and cell-based assays, including assay development, lead optimization, and RNAi formulation.
Our goal is to work collaboratively with your team to design studies that ensure you get the most informative and actionable data as efficiently as possible.
Using our OptiDIFF platform technology alongside CRISPR gene-editing capabilities, we can generate a wide range of disease models to support hit to lead compound profiling initiatives.
And, of course, you get access to our proprietary OptiDIFF platform, which is well known for generating iPSC-derived models for even "difficult" target cell types such as hepatocytes, intestinal cells and organoids, and pancreatic cells.
Move even faster by screening your candidates on our already built and ready-to-use validated models: